NCT05726461 is a NA clinical trial of AndroidAPS-rt-CGM; in Diabetes Mellitus, sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

Who is sponsoring NCT05726461?

NCT05726461 is sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

What drugs are being tested in NCT05726461?

Interventions in NCT05726461: AndroidAPS-rt-CGM;, sensor augmented pump(SAP);.

What condition does NCT05726461 study?

NCT05726461 studies Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases.

Is NCT05726461 still recruiting?

NCT05726461 is currently status unknown. Last updated 27 July 2023.

Last reviewed 2023-07-27 · How we verify

NCT05726461

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in China

Status unknown NA Last updated 27 July 2023

What this trial tests

NA trial testing AndroidAPS-rt-CGM; in Diabetes Mellitus in 25 participants. Status unknown.

Timeline

11 February 2023

Primary endpoint
30 September 2024

30 September 2024

Quick facts

Lead sponsor	Third Affiliated Hospital, Sun Yat-Sen University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	11 February 2023
Primary completion	30 September 2024
Estimated completion	30 September 2024
Sites	1 location across China

Drugs / interventions tested

AndroidAPS-rt-CGM;
sensor augmented pump(SAP);

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Glucose Metabolism Disorders — all drugs for Glucose Metabolism Disorders →
Metabolic Disease — all drugs for Metabolic Disease →

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Who can join

Adults 18 to 75, any sex, with Diabetes Mellitus or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 26-week randomized, free-living, open-label, two-arm, two-phase, crossover trial. Participants will receive two interventions at different phases, including the Android artificial pancreas system(AndroidAPS-rt-CGM) and sensor-augment pump(SAP), and use marketed rapid-acting insulin analogs (insulin Aspart, insulin Lispro, or insulin Glulisine) normally used in their usual clinical care. The safety and efficacy of AndroidAPS-rt-CGM and SAP in adult T1DM with suboptimal glycemic control will be compared to explore whether the use of AndroidAPS-rt-CGM in adult T1DM with suboptimal glycemic control will be associated with better glycemic control with no increased hypoglycemia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of Android artificial pancreas system use at home among adults with type 1 diabetes mellitus in China: protocol of a 26-week, free-living, randomised, open-label, two-arm, two-phase, crossover trial.
Lei M, Lin B, Ling P, Liu Z, et al · · 2023 · cited 4× · PMID 37558445 · DOI 10.1136/bmjopen-2023-073263
Experiences and opinions of adults with type 1 diabetes on the android-based open-source closed-loop system in China: a qualitative study.
Huang Q, Ni Y, Lei M, Ling P, et al · · 2025 · cited 1× · PMID 39819904 · DOI 10.1136/bmjopen-2024-094333

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other Third Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07409259 — PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure · EARLY_PHASE1 · active not recruiting
NCT07281664 — Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hep · NA · not yet recruiting
NCT07338552 — Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China · NA · not yet recruiting
NCT07354997 — Establishing a Virtual Health Community Management Model for Pre-Diabetes Patients · NA · completed
NCT07253233 — Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05726461 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Third Affiliated Hospital, Sun Yat-Sen University
Last refreshed: 27 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05726461.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing